These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36305180)

  • 1. Low-frequency pre-treatment HIV drug resistance: effects on 2-year outcome of first-line efavirenz-based antiretroviral therapy.
    Milne RS; Beck IA; Levine M; So I; Andersen N; Deng W; Panpradist N; Kingoo J; Kiptinness C; Yatich N; Kiarie JN; Sakr SR; Chung MH; Frenkel LM
    AIDS; 2022 Nov; 36(14):1949-1958. PubMed ID: 36305180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial.
    Chung MH; McGrath CJ; Beck IA; Levine M; Milne RS; So I; Andersen N; Dross S; Coombs RW; Chohan B; Yatich N; Kiptinness C; Sakr SR; Kiarie JN; Frenkel LM
    Lancet HIV; 2020 Feb; 7(2):e104-e112. PubMed ID: 31818716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pre-treatment HIV-drug resistance associated with virologic outcome of first-line NNRTI-antiretroviral therapy: A cohort study in Kenya.
    Beck IA; Levine M; McGrath CJ; Bii S; Milne RS; Kingoo JM; So I; Andersen N; Dross S; Coombs RW; Kiarie J; Chohan B; Sakr SR; Chung MH; Frenkel LM
    EClinicalMedicine; 2020 Jan; 18():100239. PubMed ID: 31956856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.
    Milne RS; Silverman RA; Beck IA; Mckernan-Mullin J; Deng W; Sibley TR; Dross S; Kiarie JN; Sakr SR; Coombs RW; Chung MH; Frenkel LM
    AIDS; 2019 May; 33(6):941-951. PubMed ID: 30946148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretreatment HIV Drug Resistance and Virologic Outcomes to First-Line Antiretroviral Therapy in Peru.
    Soria J; Mugruza R; Levine M; León SR; Arévalo J; Ticona E; Beck IA; Frenkel LM
    AIDS Res Hum Retroviruses; 2019 Feb; 35(2):150-154. PubMed ID: 30560685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oligonucleotide ligation assay detects HIV drug resistance associated with virologic failure among antiretroviral-naive adults in Kenya.
    Chung MH; Beck IA; Dross S; Tapia K; Kiarie JN; Richardson BA; Overbaugh J; Sakr SR; John-Stewart GC; Frenkel LM
    J Acquir Immune Defic Syndr; 2014 Nov; 67(3):246-53. PubMed ID: 25140907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.
    Geretti AM; Fox ZV; Booth CL; Smith CJ; Phillips AN; Johnson M; Li JF; Heneine W; Johnson JA
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):569-73. PubMed ID: 19779307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of minority frequency pretreatment HIV drug-resistant variants in pregnant women and associations with virologic non-suppression at term.
    Boyce CL; Beck IA; Styrchak SM; Hardy SR; Wallner JJ; Milne RS; Morrison RL; Shapiro DE; João EC; Mirochnick MH; Frenkel LM
    PLoS One; 2022; 17(9):e0275254. PubMed ID: 36166463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis.
    Li JZ; Paredes R; Ribaudo HJ; Svarovskaia ES; Metzner KJ; Kozal MJ; Hullsiek KH; Balduin M; Jakobsen MR; Geretti AM; Thiebaut R; Ostergaard L; Masquelier B; Johnson JA; Miller MD; Kuritzkes DR
    JAMA; 2011 Apr; 305(13):1327-35. PubMed ID: 21467286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.
    Paredes R; Lalama CM; Ribaudo HJ; Schackman BR; Shikuma C; Giguel F; Meyer WA; Johnson VA; Fiscus SA; D'Aquila RT; Gulick RM; Kuritzkes DR;
    J Infect Dis; 2010 Mar; 201(5):662-71. PubMed ID: 20102271
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Near point-of-care, point-mutation test to detect drug resistance in HIV-1: a validation study in a Mexican cohort.
    Panpradist N; Beck IA; Ruth PS; Ávila-Ríos S; García-Morales C; Soto-Nava M; Tapia-Trejo D; Matías-Florentino M; Paz-Juarez HE; Del Arenal-Sanchez S; Reyes-Terán G; Lutz BR; Frenkel LM
    AIDS; 2020 Jul; 34(9):1331-1338. PubMed ID: 32205723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between detection of HIV-1 DNA resistance mutations by a sensitive assay at initiation of antiretroviral therapy and virologic failure.
    Jourdain G; Wagner TA; Ngo-Giang-Huong N; Sirirungsi W; Klinbuayaem V; Fregonese F; Nantasen I; Techapornroong M; Halue G; Nilmanat A; Wittayapraparat P; Chalermpolprapa V; Pathipvanich P; Yuthavisuthi P; Frenkel LM; Lallemant M;
    Clin Infect Dis; 2010 May; 50(10):1397-404. PubMed ID: 20377404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
    Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
    Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiviral resistance and correlates of virologic failure in the first cohort of HIV-infected children gaining access to structured antiretroviral therapy in Lima, Peru: a cross-sectional analysis.
    Rath BA; von Kleist M; Castillo ME; Kolevic L; Caballero P; Soto-Castellares G; Amedee AM; Robinson JE; Katzenstein DK; Van Dyke RB; Oberhelman RA
    BMC Infect Dis; 2013 Jan; 13():1. PubMed ID: 23280237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
    Ait-Khaled M; Rakik A; Griffin P; Stone C; Richards N; Thomas D; Falloon J; Tisdale M;
    Antivir Ther; 2003 Apr; 8(2):111-20. PubMed ID: 12741623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of HIV-1 reverse transcriptase polymorphisms on responses to first-line nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-1-infected adults.
    Mackie NE; Dunn DT; Dolling D; Garvey L; Harrison L; Fearnhill E; Tilston P; Sabin C; Geretti AM; ;
    AIDS; 2013 Sep; 27(14):2245-53. PubMed ID: 24157905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria.
    Ndembi N; Murtala-Ibrahim F; Tola M; Jumare J; Aliyu A; Alabi P; Mensah C; Abimiku A; Quiñones-Mateu ME; Crowell TA; Rhee SY; Shafer RW; Gupta R; Blattner W; Charurat ME; Dakum P
    AIDS Res Ther; 2020 Nov; 17(1):64. PubMed ID: 33143751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergent HIV-1 Drug Resistance Mutations Were Not Present at Low-Frequency at Baseline in Non-Nucleoside Reverse Transcriptase Inhibitor-Treated Subjects in the STaR Study.
    Porter DP; Daeumer M; Thielen A; Chang S; Martin R; Cohen C; Miller MD; White KL
    Viruses; 2015 Dec; 7(12):6360-70. PubMed ID: 26690199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.